Merck & Co., Inc. (NYSE:MRK) EVP Sells 18,706 Shares

Key Points

• Merck EVP David Maraldo sold 18,706 shares at an average price of $128.72, generating approximately $2.41 million and reducing his holdings by 50.67% to 18,212 shares.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while adjusted EPS of $0.13 surpassed the expected $0.26 loss; revenue increased 5.1% year over year.
• The company declared a quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a 2.6% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $134.56.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP David Maraldo sold 18,706 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Merck & Co., Inc. Price Performance

MRK stock traded up $0.24 during trading on Friday, hitting $128.61. The stock had a trading volume of 6,425,060 shares, compared to its average volume of 10,766,726. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The stock has a market capitalization of $317.64 billion, a P/E ratio of 102.89, a PEG ratio of 5.14 and a beta of 0.19. The company's 50-day moving average price is $123.78 and its two-hundred day moving average price is $119.04.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business's revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 2.72 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is 272.00%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRK has been the topic of a number of recent research reports. Bank of America boosted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Scotiabank raised their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, June 30th. BMO Capital Markets boosted their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. CICC Research began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $134.56.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source